Products

ClearRead CT
RIVERAIN TECHNOLOGIES
Cardiology AI
ClearRead CT is an FDA-cleared AI suite by Riverain Technologies for cardiothoracic health, enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans. It improves diagnostic accuracy, reduces reading times, and streamlines radiology workflows through advanced AI and vessel suppression technology.
CLEARREAD +CONFIRM
RIVERAIN TECHNOLOGIES
Radiology & Imaging AI
CLEARREAD +CONFIRM is an AI tool by Riverain Technologies that enhances chest X-ray images to improve the visibility and confirmation of lines and tubes, reducing reading time by approximately 19% for radiologists.
ClearRead Xray Pneumothorax
Riverain Technologies
Radiology & Imaging AI
ClearRead Xray Pneumothorax is an AI-driven tool by Riverain Technologies that provides triage notification for suspected pneumothorax (5mm or larger) on adult chest X-rays, aiming for early detection and improved radiologist efficiency.

See all 6 products →

About Riverain Technologies

Riverain Technologies is a medical software innovator dedicated to revolutionizing early disease detection through artificial intelligence, primarily focusing on thoracic imaging. Their flagship ClearRead™ suite of FDA-cleared software tools significantly enhances a clinician’s ability to detect and characterize lung nodules and other abnormalities in thoracic CT scans and X-ray images.

By leveraging deep learning algorithms and patented suppression technologies, Riverain aims to improve diagnostic accuracy, streamline radiologist workflow, and ultimately contribute to better patient outcomes. The ClearRead solutions provide an unimpaired view by removing interfering normal structures like bones and vessels, and machine noise, allowing radiologists to focus on actionable data, complete more reads faster, and reduce missed nodules. This includes applications for lung cancer screening and diagnosis, opportunistic screening for coronary heart disease by providing coronary artery calcium (CAC) scores for ungated scans, and pneumothorax detection.

The company’s AI-powered solutions are designed to integrate seamlessly into existing PACS workflows, offering a workflow-friendly approach that supports radiologists in managing increasing imaging volumes and improving efficiency without sacrificing performance.

Focus Areas

Lung disease detection cardiothoracic disease detection pulmonary nodule detection coronary artery calcification (CAC) scoring pneumothorax detection chest X-ray CAD chest CT vessel suppression bone suppression AI in medical imaging diagnostic accuracy workflow efficiency [3 5 6 7 10 11 13 17 18 19 20 21 27 33 34]

Business Intelligence

Key InvestorsPing An Voyager Partners, Mercom Capital Group [2, 15]
PartnershipsUniversity Medical Center New Orleans (LCMC Health) [10], RevealDX [6, 8], Aidoc [12, 13, 30], Imbio [12], Volpara Health [12], Nuance [12], Sectra [12], VIDA Diagnostics [18, 29, 32], deepc [19, 29, 32], Bialogics [29, 32], Kettering Health Network [9], TriHealth [9], multiple Veterans Hospitals (VA medical centers) [6, 8, 9, 24, 27], Mercy Hospital [9], University Hospitals in Cleveland [9], University of Washington School of Medicine [6, 8, 23, 30], University of Colorado Hospital [14], Duke University Medical Center [14], Jefferson Einstein Medical Center [14]
TechnologyCloud-native or clinic deployment, advanced machine learning and AI methods, deep learning, acquisition normalization technology, patented suppression technologies (vessel suppression for CT, bone suppression for X-ray), Clear Visual Intelligence (CVI), universal PACS interoperability, compatibility and validation with major AI platforms (e.g., deepcOS, Aidoc's aiOS) [3, 4, 5, 10, 11, 13, 17, 19, 22, 27, 33, 36, 37]
FDA ClearancesMultiple, including at least 10 distinct FDA clearances across its ClearRead CT and ClearRead Xray suites. These include clearances for ClearRead CT (nodule detection, vessel suppress, detect, compare, CAC scoring) and ClearRead Xray (bone suppress, detect, pneumothorax). [3, 4, 5, 6, 8, 11, 13, 17, 19, 21, 23, 27, 32, 33] cleared products (estimated)

What Physicians Need to Know

Lung Disease Detection
Specializes in the early and accurate detection of pulmonary nodules, including solid, sub-solid, and ground-glass nodules, crucial for lung cancer screening and diagnosis. [2, 3, 4, 5, 12, 13, 16, 18, 19]
Cardiothoracic Disease Detection
Offers solutions for the detection of cardiothoracic diseases, notably providing coronary artery calcification (CAC) scoring on ungated, non-contrast CTs for opportunistic screening of coronary heart disease and cardiovascular risk assessment. [2, 3, 5, 6, 10, 14, 18, 20, 21]
Pneumothorax Detection
Provides AI-driven tools for the efficient and accurate identification of pneumothorax on chest X-rays, critical for timely intervention. [2, 4, 14]
Image Suppression Technology
Features unique, patented bone suppression technology for chest X-rays and vessel suppression technology for chest CTs, removing interfering normal structures to provide an unimpaired view of the chest. [3, 4, 5, 6, 8, 11, 14, 15, 16, 17, 18, 19]
AI in Medical Imaging
Leverages advanced AI algorithms, machine learning, and deep learning methods to enhance diagnostic accuracy, streamline radiologist workflow, and ensure consistent imaging results across diverse devices and patient populations. [2, 3, 6, 8, 11, 13, 14, 15, 17, 19, 22]
Diagnostic Accuracy & Efficiency
Proven to improve detection rates for pulmonary nodules (e.g., 29% for previously missed nodules, 17% higher on X-ray) and significantly reduce reading times (up to 36% for CT, 19% for X-ray) without compromising accuracy. [2, 5, 7, 14, 19, 20]
Physician Tip

Riverain Technologies' ClearRead solutions are designed to empower physicians by offering an 'unimpaired view' of chest imaging, thanks to their patented bone and vessel suppression technology. This clarity allows radiologists to focus precisely on actionable data, leading to improved detection of subtle pulmonary nodules, pneumothorax, and accurate coronary artery calcification (CAC) scoring for cardiovascular risk assessment. The AI-driven tools significantly enhance diagnostic accuracy and workflow efficiency, reducing reading times and easing cognitive burden, which is crucial in high-volume environments. With FDA-cleared and CE-marked solutions, physicians can trust the reliability and clinical validation of the technology, ultimately facilitating earlier detection and intervention for lung cancer and heart disease, and contributing to better patient outcomes. The seamless integration capabilities ensure minimal disruption to existing workflows. [2, 3, 4, 5, 6, 7, 8, 11, 13, 14, 16, 18, 19, 20]

Riverain Technologies' ClearRead suite is designed for seamless integration into existing clinical workflows. They have established extensive partnerships with OEMs, AI vendors (including Aidoc, Imbio, Volpara Health, RevealDX, VIDA Diagnostics, Azra AI, and deepc), PACS providers (such as Nuance and Sectra), and reporting/patient management companies. This broad ecosystem ensures interoperability and allows for deployment within various AI orchestration platforms (e.g., Aidoc's aiOS, deepcOS, VIDA Intelligence Platform, Bialogics AIQ), providing enterprise-wide access to their AI solutions without significant IT overhead or system disruption. [7, 9, 10, 12, 14, 15, 21, 22]

Products by Riverain Technologies

6 products in the directory

ClearRead CT
RIVERAIN TECHNOLOGIES
Cardiology AI
ClearRead CT is an FDA-cleared AI suite by Riverain Technologies for cardiothoracic health, enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans. It improves diagnostic accuracy, reduces reading times, and streamlines radiology workflows through advanced AI and vessel suppression technology.
CLEARREAD +CONFIRM
RIVERAIN TECHNOLOGIES
Radiology & Imaging AI
CLEARREAD +CONFIRM is an AI tool by Riverain Technologies that enhances chest X-ray images to improve the visibility and confirmation of lines and tubes, reducing reading time by approximately 19% for radiologists.
ClearRead Xray Pneumothorax
Riverain Technologies
Radiology & Imaging AI
ClearRead Xray Pneumothorax is an AI-driven tool by Riverain Technologies that provides triage notification for suspected pneumothorax (5mm or larger) on adult chest X-rays, aiming for early detection and improved radiologist efficiency.
ClearRead CT CAC
Riverain Technologies
Cardiology AI
ClearRead CT CAC by Riverain Technologies is an AI-powered software that enables opportunistic screening for coronary artery calcification (CAC) by accurately detecting, quantifying, and reporting Agatston scores from routine, ungated, non-contrast chest CT scans.
RAPIDSCREEN RS-2000
Riverain Technologies
Oncology AI
RAPIDSCREEN RS-2000 was an FDA-approved Computer-Aided Detection (CAD) system for identifying solitary pulmonary nodules on chest radiographs, developed by Deus Technologies and marketed by Riverain Medical Group (now Riverain Technologies).
DELTAVIEW MODEL
Riverain Technologies
Oncology AI
DELTAVIEW MODEL, by Riverain Technologies (formerly Riverain Medical Group), is an AI-driven medical imaging software for temporal comparison of chest X-rays, designed to detect subtle changes like early-stage lung cancer nodules through bone suppression and image subtraction technology.

What the Web Says

Riverain Technologies receives generally positive feedback for its AI-powered chest X-ray analysis software, particularly ClearRead Xray, which aids in earlier disease detection and reduces radiologist workload. Employer reviews indicate a positive work environment with good benefits, though some mention challenges with company size and growth.

Overall: Positive

Strengths

  • Improved accuracy and earlier detection of lung nodules and other abnormalities.
  • Reduces radiologist reading time and workload.
  • User-friendly interface and seamless integration with existing PACS.
  • Positive impact on patient outcomes.
  • Supportive and collaborative work environment.
  • Good benefits and opportunities for professional growth.

Limitations

  • Can be expensive for smaller healthcare facilities.
  • Some users report a learning curve for new features.
  • Limited number of reviews available on some platforms.
  • As a smaller company, some employees desire more structured career paths.
  • Occasional challenges with rapid growth and scaling.

Based on reviews from: G2, Glassdoor, KLAS Research, AuntMinnie.com, Reddit

Last updated: 2026-07-20

Videos

News, demos, and interviews about Riverain Technologies.

Loading videos...

Videos load interactively. If none appear, search YouTube for Riverain Technologies →

View all on YouTube

Press & Coverage

Riverain Technologies
New Medicare Code G0680 Creates a New Pathway to Generate Revenue for Coronary Artery Calcification (CAC)
A new Medicare code, G0680, has been introduced to provide reimbursement for AI-powered Coronary Artery Calcification (CAC) scoring, aligning with Riverain Technologies' ClearRead CT.
2026-05
JobsOhio
Riverain Technologies Expanding to Drive Growth and Advance Health Tech Innovation
Riverain Technologies is expanding its operations in Miamisburg, Ohio, creating 48 new jobs and bolstering its workforce to meet the increasing demand for its AI-powered diagnostic tools.
2026-01
Riverain Technologies
Riverain Technologies Expands Globally, Launches FDA-Cleared Technology
Riverain Technologies announced global expansion across eight countries in 2024, adding nearly 50 new customers and launching new FDA-cleared technology for coronary artery calcium (CAC) scoring on ungated CT scans.
2025-02
Aidoc Blog
Riverain Technologies and Aidoc: Faster Reads and Improved Nodule Detection
A University of Washington School of Medicine study, presented at RSNA 2024, showed that integrating Riverain Technologies' ClearRead CT with Aidoc's aiOSu2122 platform significantly reduced radiology reading times and improved pulmonary nodule detection.
2025-02
Riverain Technologies
Riverain Technologies Announces Health Canada Approval of ClearRead CT CAC for Opportunistic Coronary Artery Calcification Quantification
Health Canada has approved Riverain Technologies' ClearRead CT CAC, an AI solution for opportunistic coronary artery calcification quantification on ungated, non-contrast chest CT exams, enabling earlier detection of cardiovascular disease.
2025-03
Riverain Technologies
Riverain Technologies Brings ClearRead AI-Powered Lung Cancer Detection to Hospitals and VA Medical Centers
Riverain Technologies achieved 286% growth in 2023, expanding its AI-driven imaging technology to numerous healthcare organizations, including VA medical centers and Department of Defense facilities, for early cardiothoracic disease detection.
2024-02
AuntMinnie
Riverain secures VHA contract for ClearRead CT
Riverain Technologies secured a contract with the Veterans Health Administration (VHA) for its ClearRead AI platform, providing lung nodule detection capabilities to the VHA's Lung Precision Oncology program.
2022-11
Riverain Technologies
Riverain Technologies achieves EU MDR certification
Riverain Technologies successfully completed the rigorous EU Medical Device Regulation (MDR) Certification process on February 23, 2022, demonstrating its commitment to regulatory compliance.
2022-03

Frequently Asked Questions

Riverain Technologies' ClearRead AI solutions are designed to aid in the detection of various cardiothoracic conditions. ClearRead Xray focuses on pulmonary nodule detection, pneumothorax, and general cardiothoracic diseases by suppressing bone and optimizing portable chest X-rays. ClearRead CT enhances the detection, characterization, and tracking of pulmonary nodules (solid, part-solid, ground-glass) through vessel suppression, and also provides coronary artery calcification (CAC) scoring on ungated, non-contrast CTs.
The ClearRead solutions improve diagnostic accuracy by providing an unimpaired view of the chest through patented bone and vessel suppression technologies, leading to increased nodule detection rates and reduced missed nodules. This also streamlines workflow by reducing reading times significantly, easing cognitive load, and integrating seamlessly into existing PACS systems without requiring a separate viewer.
Riverain Technologies' ClearRead products are FDA-cleared and CE-marked, ensuring they meet stringent regulatory requirements for medical devices. The company also holds ISO27001 certification for secure and safe information management, reflecting a commitment to patient safety and data privacy.
Riverain's ClearRead solutions are designed for seamless integration into existing PACS workflows, appearing as an additional series in the patient study without needing a separate application viewer. They are device and protocol agnostic, compatible with various manufacturers' equipment, and can be deployed on-premise or in the cloud with minimal installation time, typically around four hours.
Riverain Technologies has established a broad partnership ecosystem, integrating its ClearRead solutions with major AI platforms and PACS marketplaces like Aidoc, deepc, CARPL.ai, and Siemens Healthineers. These collaborations expand product availability globally and facilitate comprehensive care, such as the partnership with Azra AI for end-to-end lung cancer care coordination from detection through survivorship.
Riverain Technologies offers dedicated customer support, including FAQs, manuals, system recommendations, and direct contact options for demos or inquiries. Their pricing model typically involves either a one-time license fee or a subscription, with costs often based on the number of analyses performed.
Founded in 2004, Riverain Technologies demonstrates strong company stability with significant growth, reporting 286% sales growth in 2023 and 147% in 2024, alongside a 100% customer retention rate in 2023. The company is expanding its global presence, adding new customers and employees, and maintains a stable core leadership team, indicating a robust and growing market position.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.